Table 1.
Baseline demographic and clinical characteristics of study participants, divided according to metformin use.
| Variable | Non-metformin (N=12,653) |
Metformin (N=37,052) |
P-value | Daily dose, g | P trend | ||
|---|---|---|---|---|---|---|---|
| <1.0 (N=19,651) |
1.0-2.0 (N=8,188) |
>2.0 (N=9,213) |
|||||
| Age, y | 64.02 (13.57) | 58.17 (12.59) | <0.001 | 58.38 (13.14) | 57.20 (11.92) | 58.60 (11.02) | <0.001 |
| Female, % | 4,968 (39.26) | 16,090 (43.43) | <0.001 | 7,953 (40.47) | 3,603 (44.00) | 4,534 (49.21) | <0.001 |
| Comorbidity index | 0.95 (0.94) | 0.90 (0.85) | <0.001 | 0.88 (0.85) | 0.89 (0.85) | 0.93 (0.87) | <0.001 |
| Number of visits/y | 15.03 (25.73) | 13.96 (25.28) | 0.015 | 13.08 (24.75) | 13.64 (24.95) | 16.13 (26.51) | <0.001 |
| Medication use, % | |||||||
| Vitamin B12 | 349 (2.76) | 905 (2.44) | 0.051 | 461 (2.35) | 176 (2.15) | 268 (2.91) | 0.001 |
| Vitamin B1 | 4,480 (35.41) | 12,436 (33.56) | <0.001 | 6,467 (32.91) | 2,576 (31.46) | 3,393 (36.83) | <0.001 |
| Antihypertensive | 9,733 (76.92) | 26,747 (72.19) | <0.001 | 13,609 (69.25) | 5,817 (71.04) | 7,321 (79.46) | <0.001 |
| Antihyperlipidemic | 7,757 (61.31) | 25,271 (68.20) | <0.001 | 12,742 (64.84) | 5,678 (69.35) | 6,851 (74.36) | <0.001 |
| NSAIDs | 5,924 (46.82) | 16,562 (44.70) | <0.001 | 8,315 (42.31) | 3,563 (43.51) | 4,684 (50.84) | <0.001 |